Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK2 | O43353 | 1/20 | 1.00 |
| ▸ | PTGER4 | P35408 | 15/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14616780 | 0.95 | RIPK2 (0.91) | RIPK2PTGER4KMT2AMEN1HPGD | |
| SCHEMBL14616782 | 0.92 | RIPK2 (0.84) | RIPK2PTGER4KMT2AHPGD | |
| SCHEMBL14616775 | 0.92 | RIPK2 (0.84) | RIPK2PTGER4 | |
| SCHEMBL14616773 | 0.91 | RIPK2 (0.83) | RIPK2PTGER4 | |
| SCHEMBL14616776 | 0.87 | RIPK2 (0.78) | RIPK2PTGER4 | |
| SCHEMBL14616783 | 0.85 | RIPK2 (0.73) | RIPK2PTGER4 | |
| SCHEMBL14576632 | 0.84 | RIPK2 (0.72) | RIPK2PTGER4KMT2AMEN1HPGD | |
| SCHEMBL14616779 | 0.84 | RIPK2 (0.72) | RIPK2PTGER4KMT2AMEN1HPGD | |
| SCHEMBL14616784 | 0.83 | RIPK2 (0.71) | RIPK2PTGER4 | |
| SCHEMBL14616785 | 0.83 | RIPK2 (0.70) | RIPK2PTGER4KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023122298-A1 | PROTEIN STABILIZING COMPOUNDS CONTAINING USP28 AND/OR USP25 TARGETING LIGANDS | Stablix, Inc. (US) | 2023-06-29 | — | — | WO | disclosed |
| US-20130018039-A1 | IMIDAZOLYL-IMIDAZOLES AS KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2013-01-17 | — | — | US | disclosed |
| US-20130018039-A1 | IMIDAZOLYL-IMIDAZOLES AS KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2013-01-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130018039-A1 | IMIDAZOLYL-IMIDAZOLES AS KINASE INHIBITORS | MAP3K19, MAP3K20, MAP3K3 | RIPK2 255/4885PTGER4 3190/4885KMT2A 536/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.